Semaglutide Studied for Severe Childhood Obesity in Kentucky Trial

University of Kentucky Launches MODERN Study for Adolescents

Researchers at the University of Kentucky have started the MODERN study (Mitigation of Cardiovascular Disease Risks in Pediatric Extreme Obesity) to examine the effects of semaglutide in adolescents with severe obesity.

The trial is led by John Bauer and Aurelia Radulescu in the UK College of Medicine, aiming to determine if semaglutide can reverse early signs of heart disease in this high-risk group.

Semaglutide’s Role and FDA Approval in Pediatric Obesity

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is already approved by the U.S. Food and Drug Administration (FDA) for use in children ages 12–18 for weight management as of 2022.

The University of Kentucky Pediatric BMI Clinic, which receives up to 1,000 new referrals annually, now serves more than 140 patients on pharmacological weight-loss management, including semaglutide.

Safety Measures and Family Involvement in Treatment

The research team emphasizes safety by providing family education, using low doses, and monitoring outcomes monthly.

Decisions to start semaglutide involve shared discussions with families, thorough communication of risks and benefits, and careful screening before prescribing any GLP-1 medication.

What the Evidence Shows and Who It Applies To

Semaglutide has been shown to be safe and effective for adolescents in previous clinical trials, leading to its FDA approval for this age group.

The MODERN study is a clinical trial focusing on adolescents with severe obesity in Kentucky, a state with one of the highest childhood obesity rates in the U.S.

Limitations and Remaining Questions About Long-Term Safety

Long-term safety data for semaglutide in children are still limited, as FDA approval for pediatric use only began in 2022.

While early animal studies raised concerns about thyroid cancer risk, human studies have not found a clear association, but the research team maintains strict screening and monitoring protocols out of caution.

Context for Metabolic Health Management

For families and clinicians managing adolescent obesity, the MODERN study highlights the need for careful consideration of both benefits and risks when using GLP-1 medications.

GLP-1 medications should only be prescribed when clinically necessary, not for cosmetic reasons, and always with appropriate medical oversight.